Josep Tabernero

Clinical Cancer Research Deputy Editor

Josep Tabernero is a Deputy Editor for Clinical Cancer Research and is currently the Head of the Medical Oncology Department at the Vall d’Hebron Barcelona Hospital campus and the Director of the Vall d’Hebron Institute of Oncology; he also leads the Research Innovation Catalonian Cancer Centers Network. His research group aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway dysregulation. He is dedicated to advancing immune-oncology and rendering anti-cancer therapies more precise, and he has a large portfolio of trials in this area.

Dr. Tabernero has been an active AACR member since 2006 and has worked on various committees for the organization. Most recently, he was a member of the program committee for the AACR Annual Meeting, a committee that he co-chaired in 2017. He also was a co-chair of the Scientific Committee for the AACR-NCI-EORTC Molecular Targets Conference in 2014. In addition to his editorial work as a Senior Editor (2010-2016) and Deputy Editor (since 2017) for Clinical Cancer Research, Dr. Tabernero has served as a Scientific Editor for Cancer Discovery since 2011.

Dr. Tabernero has received many awards over the past two decades for his work. In 2017, he was selected as the 25th Medical Embassador of the Spanish Health, and in 2018 he received the Giants of Cancer Care Award in Gastrointestinal Cancer at the ASCO Annual Meeting.

In addition to his work at AACR, Dr. Tabernero has held leadership positions in many other organizations devoted to advancing cancer research. He is the 2018-2019 president of the European Society for Medical Oncology, and chaired committees for the European Cancer Organization’s Congress in 2015. He holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain.

Dr. Tabernero’s recently published articles in AACR journals are listed below.

• Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer
  Méndez O…Villanueva J. Clinical Cancer Research December 2018.
• Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
  Gallois C…Laurent-Puig P. Clinical Cancer Research October 2018.
• Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid
  Martínez-Ricarte F…Seoane J. Clinical Cancer Research June 2018.
• Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer
  Hill AG…Tabernero J. Clinical Cancer Research May 2018.
• Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF^V600E-Mutant Colorectal Cancer
  Corcoran RB…Van Cutsem E. Cancer Discovery April 2018.
• Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
  Sveen A…Lothe RA. Clinical Cancer Research February 2018.